Latest Medicago Inc. Stories
QUEBEC CITY, April 12, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, announced today that Chief Executive Officer Andy Sheldon was named "CEO of the Year" at the recently held World Vaccine Congress in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards recognize the outstanding achievements of vaccine...
QUEBEC CITY, March 29, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced its operational and financial results for the fourth quarter and year ended December 31, 2011. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. The Company also...
Mitsubishi Tanabe Pharma Identified as Lead Investor in September 2011 Equity Financing QUEBEC CITY, March 27, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announced the establishment of a strategic alliance with Mitsubishi Tanabe Pharma Corporation (MTPC) through the execution of a Master Research...
QUEBEC CITY, QC, March 9, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Andy Sheldon, President and Chief Executive Officer of Medicago, will be presenting at the 24(th) Annual Roth Growth Stock Conference. The conference is being held March 11-14, 2012 at the Ritz Carlton Laguna Niguel...
Medicago to Receive up to $33 Million in Upfront and Milestone Payments as well as Royalties under a First Agreement to Develop a Rotavirus Vaccine QUEBEC CITY, March 6, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the establishment of a strategic alliance with Mitsubishi Tanabe Pharma...
RALEIGH, NC and QUEBEC CITY, Feb. 13, 2012 /PRNewswire/ - Medicago USA Inc., a wholly owned subsidiary of Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received the fourth milestone payment of US$3.56 million from the Defense Advanced Research Projects Agency ("DARPA"). This is part of the potential US$21 million...
QUEBEC CITY, Feb. 3, 2012 /PRNewswire/ - Medicago Inc. (TSX : MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it plans to invest approximately $4 million to enhance the capacity of the pilot production facility located in Quebec City. The Company expects this investment to accelerate preclinical and clinical development timelines of future...
QUEBEC CITY, Jan. 19, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully completed initial studies towards the development of a new VLP vaccine candidate for rabies. Over the past 12 months, as part of the Company's strategy to further develop a pipeline of products, Medicago has...
QUEBEC CITY, QC and SAINT PAUL, MN, Jan. 16, 2012 /PRNewswire/ - Medicago Inc. (MDG: TSX), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus Like Particles, and Cellectis plant sciences, a subsidiary of Cellectis SA (Alternext: ALCLS), the French specialist in genome engineering, today announced the signing of a research agreement under which Medicago and Cellectis will collaborate to...
QUEBEC CITY, Dec. 16, 2011 /PRNewswire/ - Medicago Inc. ("Medicago" or the "Corporation") (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles ("VLPs"), announces that further to the press release dated December 15, 2011, the second tranche of the investment of $22.5 million by Philip Morris Investments B.V. ("PM Investments") has now closed. This second...
